98
edits
Difference between revisions of "Programmed death-ligand 1"
Jump to navigation
Jump to search
Programmed death-ligand 1 (view source)
Revision as of 14:59, 15 November 2017
, 14:59, 15 November 2017→General
| Line 8: | Line 8: | ||
*[[IHC]] testing using a PD-L1 antibody (demonstrating positive tumour cells) predicts response to anti-PD-L1 drugs.<ref name=pmid26970723/> | *[[IHC]] testing using a PD-L1 antibody (demonstrating positive tumour cells) predicts response to anti-PD-L1 drugs.<ref name=pmid26970723/> | ||
*The plethora of companion diagnostics developed for each PD-1/ PD-L1 inhibitor has created challenges, as these assays include different IHC antibody clones, staining protocols and platforms, scoring systems, and cutoffs for defining positivity. | *The plethora of companion diagnostics developed for each PD-1/ PD-L1 inhibitor has created challenges, as these assays include different IHC antibody clones, staining protocols and platforms, scoring systems, and cutoffs for defining positivity. | ||
**Nivolumab - 28-8 (Dako) | |||
**Pembrolizumab - 22C3 (Dako) | |||
**Aterolizumab - SP142 (Ventana) | |||
**Durvalumab - SP263 (Ventana) | |||
**Avelumab - 73-10 (Dako) | |||
===Background=== | ===Background=== | ||